drugset / Trial / NCT00748046

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

NCT00748046

Phase 1 Completed 10 enrolled Bayer
NaSingle-groupOpen-labelBasic science

Summary

The purpose of the study is to investigate the safety, biodistribution, radiation dosimetry and pharmacokinetics of three intravenous escalating dose levels of Xofigo (Alpharadin).

Timeline

Start
2008-08
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Radium-223 dichloride Other / unclassified 0.05 mbq/kg
Subject Radium-223 dichloride Other / unclassified 0.1 mbq/kg
Subject Radium-223 dichloride Other / unclassified 0.2 mbq/kg